Lecrolyn

Sodium Cromoglicate, the active ingredient in Lecrolyn, is a mast cell stabilizer presented as an ophthalmic solution for ocular use. It helps control allergic conjunctivitis and other mast cell‑mediated eye inflammation in patients prone to ocular allergies. The drug is formulated for topical administration directly onto the eye surface, providing localized effect with minimal systemic absorption.

GNH USA supplies Lecrolyn as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable logistics for global distribution.

Lecrolyn, a mast cell stabilizer, is used to manage ocular allergic conditions by preventing mediator release.

- Allergic conjunctivitis: reduces ocular itching, redness, and swelling caused by allergen exposure. - Ocular allergy (seasonal or perennial): stabilizes mast cells to prevent recurrent eye irritation and watery discharge. - Mast cell‑mediated ocular inflammation: limits inflammatory response in conditions such as vernal keratoconjunctivitis. - Contact lens‑associated allergic reaction: helps maintain comfort and reduces inflammatory signs in lens wearers.

Topical ocular use of Lecrolyn may be associated with local and, rarely, systemic adverse reactions.

Common Side Effects: - Eye irritation or burning sensation: transient discomfort after instillation. - Blurred vision: temporary visual disturbance that resolves quickly. - Redness of the conjunctiva: mild injection of the eye. - Watery discharge: increased tearing.

Serious or Rare Side Effects: - Allergic contact dermatitis: hypersensitivity reaction around the eye. - Severe ocular inflammation: persistent redness, pain, or vision changes requiring medical attention.

When prescribing or dispensing Lecrolyn, consider the following precautions to ensure safe and effective use.

- Indication verification: confirm diagnosis of allergic ocular condition before use. - Contact lens use: advise patients to remove lenses before instillation and wait before reinserting. - Concomitant eye medications: schedule Lecrolyn at least five minutes apart from other drops to avoid dilution. - Pediatric use: exercise caution and follow pediatric dosing guidelines if prescribed for children. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited. - Store at ambient temperature: keep the product below 25 °C in the original container, protected from light and moisture.

Lecrolyn may interact with other ophthalmic agents or systemic drugs that affect mast cell function.

Major Interactions (Avoid): - Antihistamine eye drops containing preservatives: may increase ocular irritation when combined. - Systemic mast cell stabilizers: concurrent use offers no added benefit and may complicate assessment of efficacy.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: monitor for additive effects on ocular surface. - Topical corticosteroids: assess for overlapping anti‑inflammatory actions. - Contact lens solutions containing preservatives: observe for increased sensitivity.